Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an...Read more
With the new investment fund, the managers plan to build two new plants in San Sebastian Columbus Venture Partners already has its second fund ready to invest in companies related to health sciences. It is in the registration phase at the National Securities Market Commission (CNMV) and will be operational shortly. The expected volume is 70 million euros, reports Expansión. According to...Read more
Latest innovations and first-hand business models
This analysis, driven by the B·Womenin Industry initiative in the Basque Country and replicated in Europe, shows that the most competitive companies also have the most level playing field in terms of gender. These companies - with gender balanced teams and workplaces that value female talent - are not only increasing revenue and stimulating innovation, but they also foster more stable and sustainable business decisions. Thanks to inclusive recruitment processes, equality plans and workplace...Read more
